2-[[(butylamino)carbonyl]amino]-N-2-naphthalenyl-4-methyl-5-thiazolecarboxamide | 302960-84-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-[[(butylamino)carbonyl]amino]-N-2-naphthalenyl-4-methyl-5-thiazolecarboxamide
• 英文别名: 2-(butylcarbamoylamino)-4-methyl-N-naphthalen-2-yl-1,3-thiazole-5-carboxamide
• CAS: 302960-84-5
• 化学式: C₂₀H₂₂N₄O₂S
• 分子量: 382.486
• InChiKey: LVNSQAOLBCRQLE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  111
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Cyclic protein tyrosine kinase inhibitors
  申请人：——

  公开号：US20040054186A1

  公开（公告）日：2004-03-18

  Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.

  新型环状化合物及其盐类，含有此类化合物的药物组合物，以及使用此类化合物治疗蛋白质酪氨酸激酶相关疾病，如免疫和肿瘤疾病的方法。
• Synergistic methods and compositions for treating cancer
  申请人：——

  公开号：US20040209930A1

  公开（公告）日：2004-10-21

  Combination therapies using IGF1R inhibitors in combination with additional kinase inhibitors are described for the synergistic treatment of cancer.

  描述了使用IGF1R抑制剂与其他激酶抑制剂结合的联合疗法，用于癌症的协同治疗。
• [EN] CYCLIC PROTEIN TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS CYCLIQUES DE PROTEINE TYROSINE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2000062778A1

  公开（公告）日：2000-10-26

  Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.

  小说环状化合物及其盐，含有这些化合物的制药组合物，以及使用这些化合物治疗蛋白酪氨酸激酶相关疾病（如免疫和肿瘤疾病）的方法。
• CYCLIC PROTEIN TYROSINE KINASE INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20140206691A1

  公开（公告）日：2014-07-24

  Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.

  新型环状化合物及其盐，含有这种化合物的药物组合物，以及使用这种化合物治疗蛋白酪氨酸激酶相关疾病（如免疫和肿瘤疾病）的方法。
• Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates
  申请人：Riggs-Sauthier Jennifer

  公开号：US20120071492A1

  公开（公告）日：2012-03-22

  The invention relates to (among other things) oligomer-PTK inhibitor conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over PTK inhibitor compounds lacking a water soluble, non peptidic oligomer.

  本发明涉及寡聚体-PTK抑制剂偶联物和相关化合物（除其他事项外）。本发明中的化合物在通过多种给药途径之一给予时，表现出优于缺乏水溶性非肽寡聚体的PTK抑制剂化合物的优点。